CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

BRAIN & DEVELOPMENT is a prestigious academic journal published by ELSEVIER, renowned for its pivotal contributions to the fields of developmental neuroscience, neurology, and pediatrics. Established in 1979, this journal has become an essential resource for researchers and clinicians alike, as it explores the complexities of brain development and associated neurological disorders in children. With an impactful focus on advancing scientific understanding, BRAIN & DEVELOPMENT is currently ranked in the Q3 quartile in Developmental Neuroscience and Clinical Neurology and Q2 in Pediatrics, reflecting its significance within the medical community. Its ISSN 0387-7604 and E-ISSN 1872-7131 underline its established presence in academic literature. While the journal does not offer open access options, it continues to be a key platform for disseminating new research findings and fostering innovation in the understanding of pediatric neurological health. The journal's commitment to quality research is further evidenced by its ongoing publication trajectory up until 2024, making it a vital source of knowledge for students, professionals, and educators in related fields.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

NEUROPEDIATRICS is a prominent academic journal published by GEORG THIEME VERLAG KG, dedicated to advancing the understanding and treatment of neurological disorders in children. Established in 1980, this journal has consistently provided a platform for innovative research and clinical practice in the fields of pediatrics and neurology, culminating in its recognition across various rankings; it holds a Q2 rating in Pediatrics, Perinatology and Child Health, and Q3 in both Medicine (miscellaneous) and Neurology (clinical) as of 2023. While NEUROPEDIATRICS is not an open access journal, it remains a crucial resource for researchers, clinicians, and students who seek cutting-edge insights and evidence-based practices in the management of pediatric neurological issues. As a result, NEUROPEDIATRICS plays an indispensable role in shaping future research directions and improving health outcomes in this vital field.

Epilepsia Open is a premier open access journal dedicated to advancing the field of neurology, particularly in the area of epilepsy research and clinical practice. Published by WILEY since 2016, this journal aims to provide a platform for high-quality, peer-reviewed research that fosters collaboration among researchers, clinicians, and educators within the global neurological community. With an impactful presence in the field, it holds a prestigious Q2 ranking in both Neurology and Clinical Neurology categories as of 2023 and has been recognized for its contributions to the understanding of epilepsy through its diverse range of articles, reviews, and clinical studies. Researchers and practitioners can benefit from the journal's open access model, which ensures that valuable findings are readily available to the public, promoting further developments in treatment and care. The journal's significant visibility is reflected in its Scopus rankings, where it ranks in the top half of peer-reviewed journals in both Neurology and Neuroscience categories. For those committed to improving the lives of those affected by epilepsy, Epilepsia Open represents a crucial resource for cutting-edge knowledge and innovative practices.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

EPILEPSY RESEARCH is a distinguished journal published by Elsevier, focusing on the dynamic field of neurology with a specific emphasis on epilepsy and related neurological disorders. Since its inception in 1987, the journal has become a vital platform for disseminating cutting-edge research, contributing significantly to the understanding of epileptic conditions and their clinical implications. With an impactful presence in the academic community, EPILEPSY RESEARCH currently holds a 2023 Q2 ranking in both the Neurology and Clinical Neurology categories, reflecting its commitment to high-quality, peer-reviewed content. The journal is indexed in SCOPUS, Ranking #173/400 in Clinical Neurology and #91/192 in Neuroscience, ensuring widespread visibility and academic engagement. Although not an open access publication, it provides critical insights, findings, and reviews that are essential for researchers, clinicians, and students alike, fostering advancements in epilepsy research and treatment. For any inquiries, the journal is based at Radarweg 29, 1043 NX Amsterdam, Netherlands.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

EPILEPSIA is a premier academic journal published by Wiley, with a storied history dating back to 1909, making it a cornerstone in the field of epilepsy research and neurology. With an impressive impact factor reflecting its robust contribution to the academic community, EPILEPSIA is categorized in the top quartile (Q1) in both neurology and clinical neurology as of 2023, underscoring its significance and prestige. The journal is ranked #15 out of 192 in Neuroscience & Neurology and #34 out of 400 in Medicine & Neurology (clinical) within Scopus, indicating its essential role in advancing knowledge and treatments related to epilepsy. Researchers and clinicians are encouraged to contribute groundbreaking studies, case reports, and reviews that inform best practices and improve patient outcomes. Although EPILEPSIA currently does not offer open access options, its detailed exploration of both fundamental and clinical aspects of epilepsy ensures wide dissemination of crucial findings among professionals and students alike, furthering the understanding and management of this complex condition.